KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026

Core Insights - Keros Therapeutics (KROS) is entering 2026 with a clearer focus on operational execution and a defined catalyst stack, primarily driven by rinvatercept [1][2] - The company has shifted costs related to elritercept to Takeda, allowing for a leaner R&D base and a longer operational runway [2] Rinvatercept as a Central Value Driver - Rinvatercept is positioned as the key value driver in Keros' pipeline, designed to inhibit negative regulators of muscle and bone mass [3] - The drug aims to promote muscle regeneration, increase muscle size and strength, reduce body fat, and improve bone strength [4] Upcoming Milestones - A pivotal milestone is the expected start of a Phase II study of rinvatercept in Duchenne muscular dystrophy (DMD) in Q2 2026, which is crucial for Keros as it is their lead program [5][10] - The Phase II trial is significant as it aims to test the drug's clinical benefits against the current standard of care, glucocorticoids, which have long-term side effects [6] Regulatory Engagement for ALS - Keros plans to engage with regulatory authorities in the second half of 2026 to discuss a Phase II study for rinvatercept in amyotrophic lateral sclerosis (ALS) [7][8] Data Support and Clinical Profile - A March 2023 update indicated that rinvatercept was well tolerated with no serious adverse events, supporting its mechanism and potential benefits [9][11] - The update also highlighted increases in muscle mass, reduced fat, and higher bone density, reinforcing the drug's target engagement [11] Competitive Landscape in DMD - The DMD therapeutic area is competitive, with established players like Sarepta Therapeutics and PTC Therapeutics, necessitating Keros to demonstrate a clear clinical profile [12][14] - Sarepta has multiple therapies and recent approvals, while PTC markets Emflaza, underscoring the need for differentiation [13][14] Financial Considerations - Keros has not recorded product sales and relies on licensing and transition-service revenue, leading to potential volatility in financials until a commercial engine is defined [15] - The company ended 2025 with $287.4 million in cash, expected to fund operations into the first half of 2028, contingent on current assumptions [16]